These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 21402844

  • 1. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.
    Karlowsky JA, Adam HJ, Decorby MR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG.
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2837-46. PubMed ID: 21402844
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.
    Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PR, Walkty AJ, Hoban DJ, Zhanel GG.
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5600-11. PubMed ID: 23979759
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.
    Walkty A, Adam HJ, Laverdière M, Karlowsky JA, Hoban DJ, Zhanel GG, Canadian Antimicrobial Resistance Alliance (CARA).
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):348-55. PubMed ID: 21353964
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
    Pillar CM, Aranza MK, Shah D, Sahm DF.
    J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
    Sader HS, Flamm RK, Jones RN.
    Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
    Jia P, Zhu Y, Zhang H, Cheng B, Guo P, Xu Y, Yang Q.
    BMC Microbiol; 2022 Oct 01; 22(1):234. PubMed ID: 36182895
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
    Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN.
    Clin Infect Dis; 2012 Sep 01; 55 Suppl 3():S206-14. PubMed ID: 22903953
    [Abstract] [Full Text] [Related]

  • 10. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011.
    Flamm RK, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2014 Apr 01; 78(4):437-42. PubMed ID: 24582578
    [Abstract] [Full Text] [Related]

  • 11. Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.
    Clark C, McGhee P, Appelbaum PC, Kosowska-Shick K.
    Antimicrob Agents Chemother; 2011 May 01; 55(5):2344-51. PubMed ID: 21343467
    [Abstract] [Full Text] [Related]

  • 12. In vitro susceptibility of ceftaroline against clinically important Gram-positive cocci, Haemophilus species and Klebsiella pneumoniae in Taiwan: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012-2018.
    Jean SS, Lee WS, Ko WC, Hsueh PR.
    J Microbiol Immunol Infect; 2021 Aug 01; 54(4):627-631. PubMed ID: 32451293
    [Abstract] [Full Text] [Related]

  • 13. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
    Jones ME.
    Clin Microbiol Infect; 2007 Jun 01; 13 Suppl 2():17-24. PubMed ID: 17488372
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.
    Walkty A, Adam H, Baxter M, Denisuik A, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG.
    Antimicrob Agents Chemother; 2014 May 01; 58(5):2554-63. PubMed ID: 24550325
    [Abstract] [Full Text] [Related]

  • 17. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2008 May 01; 61(1):86-95. PubMed ID: 18385000
    [Abstract] [Full Text] [Related]

  • 18. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.
    Jones RN, Farrell DJ, Mendes RE, Sader HS.
    J Antimicrob Chemother; 2011 Apr 01; 66 Suppl 3():iii69-80. PubMed ID: 21482572
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.